Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) have been assigned an average rating of “Hold” from the ten ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $102.60.
A number of equities analysts have commented on ENTA shares. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 24th. Berenberg Bank initiated coverage on shares of Enanta Pharmaceuticals in a report on Thursday, December 13th. They issued a “hold” rating and a $80.00 price target for the company. Finally, TheStreet lowered shares of Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Monday, November 26th.
Shares of Enanta Pharmaceuticals stock traded down $0.71 during mid-day trading on Wednesday, hitting $89.92. 5,405 shares of the stock were exchanged, compared to its average volume of 247,213. Enanta Pharmaceuticals has a 12 month low of $64.08 and a 12 month high of $127.77. The stock has a market cap of $1.76 billion, a P/E ratio of 25.86 and a beta of 1.27.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Wednesday, February 6th. The biotechnology company reported $1.25 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.46 by ($0.21). Enanta Pharmaceuticals had a return on equity of 22.78% and a net margin of 36.19%. The firm had revenue of $69.89 million for the quarter, compared to the consensus estimate of $71.27 million. During the same period in the prior year, the business earned $0.59 EPS. Enanta Pharmaceuticals’s quarterly revenue was up 83.4% compared to the same quarter last year. As a group, sell-side analysts expect that Enanta Pharmaceuticals will post 1.51 EPS for the current fiscal year.
Several large investors have recently bought and sold shares of the company. Vanguard Group Inc grew its holdings in Enanta Pharmaceuticals by 30.1% in the 3rd quarter. Vanguard Group Inc now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after buying an additional 330,374 shares during the period. Vanguard Group Inc. grew its stake in shares of Enanta Pharmaceuticals by 30.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after buying an additional 330,374 shares during the period. Matarin Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at about $17,964,000. BlackRock Inc. grew its stake in shares of Enanta Pharmaceuticals by 6.5% in the 3rd quarter. BlackRock Inc. now owns 2,590,166 shares of the biotechnology company’s stock valued at $221,354,000 after buying an additional 157,166 shares during the period. Finally, First Manhattan Co. grew its stake in shares of Enanta Pharmaceuticals by 22.7% in the 3rd quarter. First Manhattan Co. now owns 698,434 shares of the biotechnology company’s stock valued at $59,688,000 after buying an additional 129,026 shares during the period. Institutional investors and hedge funds own 87.23% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Featured Article: What is a Derivative?
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.